Tuesday, June 22, 2021 3:43:25 PM
I listened to presentations given by a biotech with a relatively new commercialized drug talking on a Zoom conference with Goldman Sachs and Raymond James. The nexus of the agreement between both company analysts and the biotech is this...
Even now, healthcare workers able to write scripts are still only having "live interactions" (aka seeing patients) and able to write scripts or provide hands on in-person healthcare 70% of where they were pre-pandemic (and please do not tell me how your PCP is different, this is an accepted industry wide number that all pharma is dealing with). Moreover, the belief is that it will take at least nine more months to achieve pre-pandemic levels of interactions. The salient point is that across the board commercial activities have led to a decline in Q-Q revenues by many pharma companies that have relatively new products they are commercializing. Elite's experience this past year is no different than others. However, according to the all-knowing Goldman Sachs, the belief is that not only will companies return to pre-pandemic sales but the expectation is an additional bump up resulting from pent-up or suppressed demand.
Despite arguments to the contrary, Elite is not operating in a vacuum and does not control the external environment.
As to this...
I thought I was crystal clear that what Elite wanted to do was impaired by the ability to fund its development, which has been ameliorated by becoming CFP. As for the p/s, I thought I was equally clear...the very fact that the p/s has been suppressed was evidence of a malignant intent to make it difficult for it to fund the business through LPC. And...those days are gone. But the effort to play games remains with the p/s remains, but I already provided a link on that three times and need not do it again.
As to uplisting to the Nasdaq...at this point is it not clear what that really means?
Recent ELTP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/28/2024 09:23:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/23/2024 12:27:32 PM
- ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • InvestorsHub NewsWire • 10/23/2024 12:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2024 08:47:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM